Defective DNA repair mechanisms in prostate cancer: Impact of olaparib

Francesca De Felice, Vincenzo Tombolini, Francesco Marampon, Angela Musella, Claudia Marchetti

Research output: Contribution to journalArticle


The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, olaparib seems to be efficacious and well tolerated. Waiting for randomized phase III trials, olaparib should be considered as a promising treatment option for PC.
Original languageEnglish
Pages (from-to)547-552
Number of pages6
JournalDrug Design, Development and Therapy
Publication statusPublished - 2017


  • BRCA
  • Castration resistant
  • DNA-repair
  • Metastatic disease
  • Olaparib
  • PARP
  • Prostate cancer


Dive into the research topics of 'Defective DNA repair mechanisms in prostate cancer: Impact of olaparib'. Together they form a unique fingerprint.

Cite this